Jazz Pharmaceuticals
JAZZ
468 hedge funds and large institutions have $7.59B invested in Jazz Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 59 funds opening new positions, 156 increasing their positions, 149 reducing their positions, and 54 closing their positions.
81% more call options, than puts
Call options by funds: $65.9M | Put options by funds: $36.3M
9% more first-time investments, than exits
New positions opened: 59 | Existing positions closed: 54
5% more repeat investments, than reductions
Existing positions increased: 156 | Existing positions reduced: 149
0% more funds holding
Funds holding: 468 → 468 (0)
1.14% less ownership
Funds ownership: 92.03% → 90.89% (-1.1%)
10% less funds holding in top 10
Funds holding in top 10: 10 → 9 (-1)
15% less capital invested
Capital invested by funds: $8.95B → $7.59B (-$1.35B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$75.6M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$54.9M |
| 3 |
Prudential Financial
Newark,
New Jersey
|
+$46.1M |
| 4 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$39M |
| 5 |
TAM
Todd Asset Management
Louisville,
Kentucky
|
+$25.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$108M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$92.9M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$60M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$58.2M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$50.5M |
JAZZ Hedge Fund Activity: Q3 2022 in Review
468 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Jazz Pharmaceuticals (JAZZ) for Q3 2022, worth a combined $7.59B — down 15% from $8.95B a quarter earlier.
Buyers outnumbered sellers: 59 funds opened new JAZZ positions and 54 closed out — a net gain of 5 holders — while 156 added to existing stakes and 149 trimmed.
The largest buyer was Arrowstreet Capital, adding an estimated $75.6M. The largest seller was Citadel Advisors, exiting entirely with an estimated $108M sold.
- 468 institutional investors held Jazz Pharmaceuticals (JAZZ) as of Q3 2022, unchanged from Q2 2022.
- Funds reported $7.59B of Jazz Pharmaceuticals stock for Q3 2022, down 15% quarter-over-quarter.
- 59 funds opened new Jazz Pharmaceuticals positions in Q3 2022 and 54 closed out, a net change of +5 holders.
- The largest Jazz Pharmaceuticals buyer in Q3 2022 was Arrowstreet Capital, an estimated $75.6M added.
- The largest Jazz Pharmaceuticals seller in Q3 2022 was Citadel Advisors, an estimated $108M sold.
Based on aggregated 13F filings for Q3 2022.